SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update
SCYNEXIS reported the closing of an exclusive license agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets). SCYNEXIS received an upfront pay...
Irina Koffler David Angulo Hansoh Pharma Triterpenoid Antifungals Preclinical Development Program European Congress
Source: businessinsider.com